Urine miRNA Biomarker for Gastrointestinal Cancer Screening Test

Screening test for early stage gastric cancer, esophageal cancer and colorectal cancer patients by measuring urine miRNAs specific to each cancer.

Advantage and Core Benefit

  • Higher sensitivity than conventional screening test and blood biomarker like CEA and CA19-9
  • Distinguishable between gastric cancer, esophageal cancer and colorectal cancer
  • Minimally invasive and easy to collect

Background and Technology

Gastric or colorectal endoscopy and biopsy is gold standard for diagnosis of gastrointestinal cancer. However, it is not applicable for early examination and screening because of high invasive and high cost. Screening is looking for cancer and the risk before a person has any symptoms. This can help find cancer at an early stage. When abnormal tissue or cancer is found early, it may be easier to treat. By the time symptoms appear, cancer may have begun to spread.

Based on fair evidence, conventional screening with barium-meal photofluorography, fecal occult blood test or serum pepsinogen (CEA, CA19-9) would not result in a decrease in mortality from gastrointestinal cancer. Novel screening markers with minimally invasive are required.

We analyzed urine sample from healthy people and relatively early stage gastric cancer, esophageal cancer and colorectal cancer patients and identified specific miRNAs expressed in the each cancer patient urine. We found that these miRNAs in urine indicated higher sensitivity for gastrointestinal cancer than the conventional biomarkers in blood. We think that the urine miRNAs can be biomarkers for gastrointestinal cancer screening.


  • Urinary miRNA biomarkers were identified by using miRNA array analysis with healthy volunteers and each cancer patients
  • The identified biomarkers were validated by accuracy measurement of urinary miRNAs panel with another healthy volunteer and each cancer patient groups. Right figure shows validation data for gastric cancer.
  • The identified miRNAs were also changed in tumor tissue and blood.



Pending, unpublished


Takaya SHIMURA (Nagoya City University)


We are looking for a partner company to develop this technology as screening test for early stage gastrointestinal cancer patients under a royalty bearing license agreement with the university.

Product No : CD-02718

Other than Medicine


Inquiry Form

Your Name (*Required)

E-Mail Address (*Required)

Company Name


Following submission of your inquiry

We will contact you shortly to discuss confidentiality, materials transfer, evaluation steps, and licensing opportunities.


Our support is provided free of charge.
The information submitted on this form is for business development use only.

About Bionauts.jp Tech Manage Corp.
Copyright © Tech Manage Corp. All Rights Reserved.